Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other Non-Current Assets (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Other Non-Current Assets data on record, last reported at $33694.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 0.53% year-over-year to $33694.0; the TTM value through Sep 2025 reached $33694.0, down 0.53%, while the annual FY2024 figure was $32109.0, 79.48% up from the prior year.
  • Other Non-Current Assets reached $33694.0 in Q3 2025 per GANX's latest filing, roughly flat from $33752.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $86998.0 in Q3 2021 and bottomed at $16534.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $34496.8, with a median of $31145.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: tumbled 79.31% in 2022, then skyrocketed 92.35% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $22111.0 in 2021, then skyrocketed by 39.38% to $30818.0 in 2022, then plummeted by 41.95% to $17890.0 in 2023, then skyrocketed by 79.48% to $32109.0 in 2024, then increased by 4.94% to $33694.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $33694.0 in Q3 2025, $33752.0 in Q2 2025, and $32641.0 in Q1 2025.